Catalent Pharma Solutions, which provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products, says it will invest nearly $14 million to expand biologics packaging capabilities and capacity at its biologics manufacturing facility in Bloomington.
The 15,000-sq.-ft. facility infrastructure will include five new packaging suites and a new quality control laboratory. Installation and commissioning of new equipment will be phased throughout the year, including both a semi-automated and fully-automated top loading cartoner, an accessorized combination syringe assembly machine, an automated auto-injector assembly machine, and two semi-automatic visual inspection machines.
The expansion is estimated to create 36 new jobs at the site, which was acquired by Catalent last year. The company’s 875,000-sq.-ft. biologics development and manufacturing facility in Bloomington employs 900 staff. The site recently achieved regulatory approval for a 20th commercial product.
Construction is set to be completed in February 2019.